ELMWOOD PARK, N.J.,
Jan. 13, 2021 /PRNewswire/
-- BioReference Laboratories, Inc., an OPKO
Health company (NASDAQ:OPK), today
introduced Scarlet Health™, an in-home, fully
integrated digital platform providing access
to on-demand diagnostic services. Scarlet has been designed
similarly to tools consumers use daily, in
order to provide ease-of-use and ubiquitous
conveniences.
BioReference introduced Scarlet, an in-home, fully integrated
digital platform providing access to diagnostic services.
Backed by BioReference's national presence and
infrastructure, with laboratory facilities and professionals
across the country, Scarlet delivers an innovative,
flexible, mobile alternative to traditional patient
service
centers or other draw locations when
phlebotomy and other specimen collection services
are needed.
Patients will no longer need to travel for laboratory
services. Healthcare providers will secure vital
diagnostic information
about patients reliably, quickly and
easily to enable a faster diagnosis.
To use Scarlet's convenient, secure and safe
approach to mobile specimen collection services, patients
will obtain a link after visiting or
connecting virtually with their healthcare
provider. After confirming the services needed, a patient
will verify their identity and schedule a date and
time, and choose their preferred location (i.e., at
their office or home) for a qualified healthcare
professional to
collect their test specimen. Patients will
then receive real-time updates and relevant
information, such as learning how to prepare for the
visit or track the healthcare professional's arrival. Specimens
will be sent to BioReference for
testing, and the results will
be securely shared online with the patient
and their ordering healthcare provider.
"Scarlet reimagines the delivery of health care, creating an
accessible, consumer-centric approach to the way patients receive
laboratory services," said Richard Schwabacher, Senior Vice
President of Digital Health and Chief Digital
Officer for BioReference Laboratories. "Scarlet
is the first of many digital health advances
at BioReference that aim to increase flexibility and
convenience for patients. We're proud to bring this kind of
innovation and technology to patients and are looking forward to
expanding access to critical health care needs
with Scarlet."
Investment in telemedicine has more than doubled in the last
year to $1.6 billion, a dramatic
acceleration attributable to the COVID-19 pandemic and
the growing demand for the tools and flexibility that digital
health offers.1 Scarlet provides a much-needed
service that is efficient, secure, convenient, flexible, digitally
enabled and easy to use, providing access to a variety of
tests, from COVID-19 to chronic conditions, and
more.
"The future of health care is at home. We're helping to
make in-home health care real for millions of
Americans by bringing diagnostic services directly
to the patient," said Jon R. Cohen,
M.D., Executive Chairman
of BioReference Laboratories. "According to PwC
Health Research Institute Health's 2020 executive survey,
40% of healthcare providers cited
laboratory challenges as a concern with growing
telehealth programs. By adding just a few key strokes to
what healthcare providers are already doing, Scarlet improves
and encourages patient-centered health care, utilizing a
similar on-demand format that patients use every day from
the comfort of their homes. With
Scarlet, BioReference removes a disconnect
between telemedicine and traditional health care, and
revolutionizes how healthcare is provided."
Scarlet services are currently available
in select markets. For more information on Scarlet,
visit www.scarlethealth.com.
About BioReference Laboratories, Inc.
BioReference provides comprehensive testing to physicians,
clinics, hospitals, employers, government units, correctional
institutions, and medical groups. BioReference offers
test services that yield high-quality and accurate results,
including a molecular test for helping with COVID-19 diagnosis and
a serology test to help indicate possible COVID-19 exposure. The
company is in network with the five largest health plans in
the United States, operates a
network of 11 laboratory locations, and is backed by a medical
staff of more than 120 M.D., Ph.D.
and other professional level clinicians and scientists. With a
leading position in the areas of genetics, women's health, maternal
fetal medicine, oncology, and urology, BioReference and
its specialty laboratories, GenPath and GeneDx, are advancing the
course of modern medicine. For more information, visit
www.bioreference.com.
About OPKO Health
OPKO is a multinational biopharmaceutical and diagnostics company
that seeks to establish industry-leading positions in large,
rapidly growing markets by leveraging its discovery, development,
and commercialization expertise and novel and proprietary
technologies. For more information,
visit www.opko.com.
Cautionary Statement Regarding Forward-Looking
Statements
This press release contains "forward-looking statements," as that
term is defined under the Private Securities Litigation Reform Act
of 1995 (PSLRA), which statements may be identified by words such
as "expects," "plans," "projects," "will," "may," "anticipates,"
"believes," "should," "intends," "estimates," and other words of
similar meaning, particularly statements regarding
BioReference's Scarlet Health mobile service, the availability
of and demand for the service, whether the service and
the integrated platform will function or perform as
designed, the role and value of the service to patients
and healthcare providers and whether the demand for at home
health care will continue or increase as anticipated, as well as
other non-historical statements about our expectations, beliefs or
intentions regarding our business, technologies and products,
financial condition, strategies or prospects. Many factors could
cause our actual activities or results to differ materially from
the activities and results anticipated in forward-looking
statements. These factors include those described in the OPKO
Health, Inc. Annual Reports on Form 10-K filed and to be filed with
the Securities and Exchange Commission and in its other filings
with the Securities and Exchange Commission. In addition,
forward-looking statements may also be adversely affected by
general market factors, competitive product development, product
availability, federal and state regulations and legislation, the
regulatory process for new products, among other factors. The
forward-looking statements contained in this press release speak
only as of the date the statements were made, and we do not
undertake any obligation to update forward-looking statements. We
intend that all forward-looking statements be subject to the
safe-harbor provisions of the PSLRA.
References:
1. PwC Health
Research Institute Health's 2020 executive survey
View original content to download
multimedia:http://www.prnewswire.com/news-releases/opko-healths-bioreference-laboratories-introduces-scarlet-health-an-in-home-diagnostic-service-to-expand-digital-health-access-301207796.html
SOURCE BioReference Laboratories, Inc